174 related articles for article (PubMed ID: 34647140)
1. Risk for ketonaemia in type 1 diabetes pregnancies with sensor-augmented pump therapy with predictive low glucose suspend compared with low glucose suspend: a crossover RCT.
Benhalima K; van Nes F; Laenen A; Gillard P; Mathieu C
Diabetologia; 2021 Dec; 64(12):2725-2730. PubMed ID: 34647140
[TBL] [Abstract][Full Text] [Related]
2. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial.
Forlenza GP; Li Z; Buckingham BA; Pinsker JE; Cengiz E; Wadwa RP; Ekhlaspour L; Church MM; Weinzimer SA; Jost E; Marcal T; Andre C; Carria L; Swanson V; Lum JW; Kollman C; Woodall W; Beck RW
Diabetes Care; 2018 Oct; 41(10):2155-2161. PubMed ID: 30089663
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of insulin pump therapy with predictive low glucose suspend feature in decreasing hypoglycemia in children with type 1 diabetes mellitus: A systematic review and meta-analysis.
Alotaibi A; Al Khalifah R; McAssey K
Pediatr Diabetes; 2020 Nov; 21(7):1256-1267. PubMed ID: 32738022
[TBL] [Abstract][Full Text] [Related]
4. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy.
Danne T; Kordonouri O; Holder M; Haberland H; Golembowski S; Remus K; Bläsig S; Wadien T; Zierow S; Hartmann R; Thomas A
Diabetes Technol Ther; 2011 Nov; 13(11):1129-34. PubMed ID: 21827318
[TBL] [Abstract][Full Text] [Related]
5. Impact of Sensor-Augmented Pump Therapy with Predictive Low-Glucose Suspend Function on Glycemic Control and Patient Satisfaction in Adults and Children with Type 1 Diabetes.
Beato-Víbora PI; Quirós-López C; Lázaro-Martín L; Martín-Frías M; Barrio-Castellanos R; Gil-Poch E; Arroyo-Díez FJ; Giménez-Álvarez M
Diabetes Technol Ther; 2018 Nov; 20(11):738-743. PubMed ID: 30256132
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.
Bosi E; Choudhary P; de Valk HW; Lablanche S; Castañeda J; de Portu S; Da Silva J; Ré R; Vorrink-de Groot L; Shin J; Kaufman FR; Cohen O;
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):462-472. PubMed ID: 31047902
[TBL] [Abstract][Full Text] [Related]
7. Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial.
Kim JY; Jin SM; Kang ES; Kwak SH; Yang Y; Yoo JH; Bae JH; Moon JS; Jung CH; Bae JC; Suh S; Moon SJ; Song SO; Chon S; Kim JH
Diabetologia; 2024 Jul; 67(7):1235-1244. PubMed ID: 38634887
[TBL] [Abstract][Full Text] [Related]
8. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes.
Collyns OJ; Meier RA; Betts ZL; Chan DSH; Frampton C; Frewen CM; Hewapathirana NM; Jones SD; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; Wheeler BJ; de Bock MI
Diabetes Care; 2021 Apr; 44(4):969-975. PubMed ID: 33579715
[TBL] [Abstract][Full Text] [Related]
9. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial.
Oskarsson P; Antuna R; Geelhoed-Duijvestijn P; Krӧger J; Weitgasser R; Bolinder J
Diabetologia; 2018 Mar; 61(3):539-550. PubMed ID: 29273897
[TBL] [Abstract][Full Text] [Related]
10. Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial.
Brown SA; Beck RW; Raghinaru D; Buckingham BA; Laffel LM; Wadwa RP; Kudva YC; Levy CJ; Pinsker JE; Dassau E; Doyle FJ; Ambler-Osborn L; Anderson SM; Church MM; Ekhlaspour L; Forlenza GP; Levister C; Simha V; Breton MD; Kollman C; Lum JW; Kovatchev BP;
Diabetes Care; 2020 Aug; 43(8):1822-1828. PubMed ID: 32471910
[TBL] [Abstract][Full Text] [Related]
11. Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study.
Lepore G; Scaranna C; Corsi A; Dodesini AR; Trevisan R
Diabetes Technol Ther; 2020 Apr; 22(4):321-325. PubMed ID: 31617752
[TBL] [Abstract][Full Text] [Related]
12. Prospective Open-Label, Single-Arm, Single-Center Follow-Up Study of the Application of the Advanced Hybrid Closed Loop System in Well-Controlled Children and Adolescents with Type 1 Diabetes.
Seget S; Rusak E; Polanska J; Jarosz-Chobot P
Diabetes Technol Ther; 2022 Nov; 24(11):824-831. PubMed ID: 35852811
[No Abstract] [Full Text] [Related]
13. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
[TBL] [Abstract][Full Text] [Related]
14. Real-world outcomes of two different sensor-augmented insulin pumps with predictive low glucose suspend function in type 1 diabetes patients.
Moreno-Fernandez J; Beato-Vibora P; Olvera P; Garcia-Seco JA; Gallego-Gamero F; Herrera MT; Muñoz-Rodriguez JR
Diabetes Res Clin Pract; 2021 Nov; 181():109093. PubMed ID: 34653567
[TBL] [Abstract][Full Text] [Related]
15. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.
Bally L; Thabit H; Tauschmann M; Allen JM; Hartnell S; Wilinska ME; Exall J; Huegel V; Sibayan J; Borgman S; Cheng P; Blackburn M; Lawton J; Elleri D; Leelarathna L; Acerini CL; Campbell F; Shah VN; Criego A; Evans ML; Dunger DB; Kollman C; Bergenstal RM; Hovorka R
BMJ Open; 2017 Jul; 7(7):e016738. PubMed ID: 28710224
[TBL] [Abstract][Full Text] [Related]
16. Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover Study.
Sharifi A; De Bock MI; Jayawardene D; Loh MM; Horsburgh JC; Berthold CL; Paramalingam N; Bach LA; Colman PG; Davis EA; Grosman B; Hendrieckx C; Jenkins AJ; Kumareswaran K; Kurtz N; Kyoong A; MacIsaac RJ; Speight J; Trawley S; Ward GM; Roy A; Jones TW; O'Neal DN
Diabetes Technol Ther; 2016 Dec; 18(12):772-783. PubMed ID: 27835037
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of the low-glucose suspend feature of insulin pump during fasting during Ramadan in type 1 diabetes mellitus.
Elbarbary NS
Diabetes Metab Res Rev; 2016 Sep; 32(6):623-33. PubMed ID: 26789012
[TBL] [Abstract][Full Text] [Related]
18. Lower versus standard sucrose dose for treating hypoglycemia in patients with type 1 diabetes mellitus in therapy with predictive low glucose suspend (PLGS) augmented insulin pumps: A randomized crossover trial in Santiago, Chile.
Grassi B; Onetto MT; Zapata Y; Jofré P; Echeverría G
Diabetes Metab Syndr; 2021; 15(3):695-701. PubMed ID: 33813244
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France.
Roze S; Smith-Palmer J; Valentine W; Payet V; de Portu S; Papo N; Cucherat M; Hanaire H
Diabetes Technol Ther; 2016 Feb; 18(2):75-84. PubMed ID: 26646072
[TBL] [Abstract][Full Text] [Related]
20. Threshold-based insulin-pump interruption for reduction of hypoglycemia.
Bergenstal RM; Klonoff DC; Garg SK; Bode BW; Meredith M; Slover RH; Ahmann AJ; Welsh JB; Lee SW; Kaufman FR;
N Engl J Med; 2013 Jul; 369(3):224-32. PubMed ID: 23789889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
